Loading organizations...
§ Private Profile · Beijing, Beijing, China
Genomics services company offering non-invasive prenatal testing (NIPT), NGS diagnostics, and bioinformatics for clinical and research applications.
Annoroad is a genomics services company based in Beijing, China, that specializes in non-invasive prenatal testing, next-generation sequencing diagnostic systems, and bioinformatics solutions. The enterprise operates multiple large-scale medical laboratories across the country and has raised approximately $106 million in total venture funding, including a $100 million Series C financing round in 2017. Positioned as a top-three provider of sequencing services in the Chinese market, the firm generates revenue by providing clinical diagnostics, oncology testing, and genetic research solutions to hospitals, universities, and pharmaceutical companies. Annoroad is backed by prominent institutional investors such as SAIF Partners, SoftBank China Venture Capital, and Ping An Ventures. Additionally, the organization has formed strategic technology and development partnerships with major industry players including Illumina and Alibaba Cloud. Annoroad was founded in 2012 by Junbin Liang, Dawei Chen, and Jianhui Li.
Annoroad has raised $105.0M across 1 funding round.
Annoroad has raised $105.0M in total across 1 funding round.
Annoroad has raised $105.0M in total across 1 funding round.
Annoroad's investors include GTJA Investment Group, Ping An Ventures, SAIF Partners, SBCVC.
Annoroad has raised $105.0M across 1 funding round. Most recently, it raised $105.0M Series C in November 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 3, 2017 | $105M Series C | Gtja Investment Group, Ping AN Ventures | Saif Partners, SBCVC | Announced |